VivoSim Labs (VIVS) Non-Current Deffered Revenue (2013 - 2019)
VivoSim Labs (VIVS) posted quarterly Non-Current Deffered Revenue of $588000.0 for Q1 2019, up 2994.74% year-over-year from $19000.0 in Q1 2018, and down 2.0% quarter-over-quarter from $600000.0 in Q4 2018.
VivoSim Labs (VIVS) Non-Current Deffered Revenue (2013 - 2019) Analysis & Trends
VivoSim Labs' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $588000.0 for Q1 2019.
- In Q1 2019, Non-Current Deffered Revenue rose 2994.74% year-over-year to $588000.0; the TTM figure through Mar 2019 stood at $588000.0 (up 2994.74% YoY), while the FY2019 annual figure was $588000.0, up 2994.74% from the prior year.
- Non-Current Deffered Revenue for Q1 2019 stood at $588000.0, down from $600000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $868000.0 in Q2 2016, with the low at $7000.0 in Q3 2015.
- The 5-year median for Non-Current Deffered Revenue is $613000.0 (2017), against an average of $496615.4.
- The sharpest annual moves came in 2016 and 2018: Non-Current Deffered Revenue soared 11742.86% in 2016, then plunged 98.59% in 2018.
- VivoSim Labs' Non-Current Deffered Revenue stood at $7000.0 in 2015, then jumped by 11128.57% to $786000.0 in 2016, then slipped by 22.01% to $613000.0 in 2017, then slipped by 2.12% to $600000.0 in 2018, then slipped by 2.0% to $588000.0 in 2019.
- Business Quant data shows VIVS's Non-Current Deffered Revenue at $588000.0 in Q1 2019, $600000.0 in Q4 2018, and $10000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 588,000.00 |
| Dec 31, 2018 | 600,000.00 |
| Jun 30, 2018 | 10,000.00 |
| Mar 31, 2018 | 19,000.00 |
| Dec 31, 2017 | 613,000.00 |
| Sep 30, 2017 | 661,000.00 |
| Jun 30, 2017 | 707,000.00 |
| Mar 31, 2017 | 749,000.00 |
| Dec 31, 2016 | 786,000.00 |
| Sep 30, 2016 | 829,000.00 |
| Jun 30, 2016 | 868,000.00 |
| Sep 30, 2015 | 7,000.00 |
| Jun 30, 2015 | 19,000.00 |
| Dec 31, 2014 | 44,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 3,000.00 |
| Mar 31, 2014 | 4,000.00 |
| Dec 31, 2013 | 5,000.00 |
| Sep 30, 2013 | 6,000.00 |
| Mar 31, 2013 | 9,000.00 |